Enhertu recommended for EU approval in early HER2-positive breast cancer

PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS

Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts

Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase

Jubilant Therapeutics reports preliminary clinical data from Phase 1/2 study in myeloproliferative neoplasms at SOHO 2026

GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma

Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer

AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial

GSK reports positive Jideytro data supporting potential first-line lung cancer use

Akeso presents positive results from registrational Phase III study of ivonescimab

ABL Diagnostics files bid to acquire IntegraGen

Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer

Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart

Kazia Therapeutics doses first patient in paediatric AT/RT study

Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer